Company / Accounts Receivable
Bio-Techne Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$206.9M
FY2025
5-year range
$145.4M / $241.4M
FY2021-FY2025
Trend
-14.3%
vs FY2024
Sector context
#69 of 138
Health Care
What the data says
At $207M, Bio-Techne's accounts receivable ranks #69 of 138 in the Health Care sector. Accounts Receivable has fluctuated over the past 10 years, ranging from $93M in FY2016 to $241M in FY2024.
Based on SEC 10-K filings.
$207M in FY2025 with a 5-year CAGR of +11.0%.
Declined from $218M to $207M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +2.1%
- 5-Year CAGR
- +11.0%
- 10-Year CAGR
- -
Sector benchmark
#69 of 138 in Health CareTop 50% of 138This company $206.9M Sector average $1.3B
▼
-84.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.0%, indicating consistent growth.
- In FY2025, accounts receivable decreased 14.3% year-over-year.
- Ranks #69 out of 138 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $206.9M | -14.3% |
| FY2024 | $241.4M | +10.5% |
| FY2023 | $218.5M | +12.3% |
| FY2022 | $194.5M | +33.8% |
| FY2021 | $145.4M | +18.6% |
| FY2020 | $122.5M | -10.9% |
| FY2019 | $137.5M | +14.3% |
| FY2018 | $120.3M | +3.0% |
| FY2017 | $116.8M | +25.1% |
| FY2016 | $93.4M | +33.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026